View Older Stories

Jan 8, 2015 02:12PM ISIS Pharmaceuticals (ISIS) PT Raised to $80 at Needham & Company on Business Strength

Dec 8, 2014 02:11PM Needham & Company Comments on ISIS Pharmaceuticals (ISIS) Following Data at ASH

Oct 29, 2014 06:50AM Regulus Therapeutics (RGLS) 5.29M Offering Prices at $17/Share

Feb 21, 2014 11:24AM Needham & Company Ratchets Price Target on ISIS Pharmaceuticals (ISIS) to $61 on Positive Data

Jan 22, 2014 10:51AM Notable Analyst Rating Changes 01/22: (GTE) (SIMO) (CVS) Upgraded; (MOS) (VZ) (ABX) Downgraded

Sep 23, 2013 02:13PM ISIS Pharmaceuticals (ISIS) PT Raised to $46 at Needham & Company on Positive Data

Aug 5, 2013 09:40AM Pre-Open Stock Movers 8/5: (CGEN) (VRNG) (TSN) Higher; (FOSL) (CBOE) (QCOM) Lower (more...)

Jul 23, 2013 10:43AM Notable Analyst Rating Changes 07/23: (TSS) (BHI) (ABX) Upgraded; (QSII) (BNNY) (ISIS) Downgraded

Jul 22, 2013 08:17AM Needham & Company Lifts PT on ISIS Pharmaceuticals (ISIS)

Jun 24, 2013 11:40AM Needham & Company Boosts ISIS Pharmaceuticals (ISIS) PT to $29

Jun 4, 2013 07:58AM Needham & Company Upbeat on ISIS Pharmaceuticals (ISIS) Following ASCO

Oct 19, 2012 01:43PM Needham Reiterates Buy on ISIS (ISIS) Following Narrow FDA Vote for Approval of Kynamro

Oct 4, 2012 04:09PM Regulus Therapeutics (RGLS) IPO Closes 5% Higher

May 22, 2012 07:20AM Needham & Company Starts ISIS Pharmaceuticals (ISIS) at Buy; Looking Beyond Kynamro at Significant Pipeline Value

Aug 8, 2011 08:27AM Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); 2Q11/Early 3Q11 Review - Mipomersen Application in EU (Submitted) and US (Expected by YE11)

Apr 14, 2011 07:52AM Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Pipeline Progress Review – Long-Term, Early Stage Programs Are Encouraging

Mar 1, 2011 10:31AM Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Strong Focus on Mipomersen Next Steps by Genzyme, Steady Progress of Early-Stage Pipeline

Jan 11, 2011 07:49AM Needham & Company Reiterates a 'Hold' on ISIS Pharmaceuticals (ISIS); FDA Views Mipomersen Data as Sufficient to Submit HoFH NDA

Aug 4, 2010 02:45PM Shares of Isis Pharma (ISIS) Volatile Following Mid-Day Downgrade by Needham

Jun 18, 2010 07:56AM Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS), Well Positioned to Address Genetic Disorders

Jun 3, 2010 07:38AM Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Annual Meeting Highlighted

May 20, 2010 07:56AM Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Pipelines to Address Cancer Through Antisense Technology

Apr 15, 2010 07:56AM Needham & Company reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Cardiovascular Program Update – Multiple Well-Characterized Drug Candidates

Feb 11, 2010 09:40AM Analysts Thoughts On Isis Pharmaceuticals (ISIS) After 19% Sell-Off

Aug 8, 2008 09:59AM Notable Analyst Rating Changes 8/8: DCP, Q, ISIS, FSYS Upgraded; BAC, ABK, VOD, KNOT, ANAD Downgraded

Aug 8, 2008 09:29AM Needham Upgrades ISIS Pharmaceuticals (ISIS) to Buy

Apr 25, 2008 01:04PM Needham Downgrades ISIS Pharma (ISIS) to Hold On Mipomersen Delays

View Older Stories